- Actinogen Medical (ACW) is set to expand its intellectual property portfolio with two new patents
- The healthcare stock filed the applications for its lead drug candidate, an Alzheimer’s treatment known as Xanamen
- Positively, the new submissions could extend the drug’s patent life protection up to 2040
- ACW’s first patent covers a process which seeks to improve cognitive function or treat cognitive decline in healthy adults
- Meanwhile, the second patent will protect Actinogen’s scale-up manufacturing process
- Actinogen closed steady following today’s news, with shares worth 2.2 cents each
